Institutional Clinical and Translational Science Award

机构临床和转化科学奖

基本信息

批准号：
9261656
负责人：
GARRET A FITZGERALD
金额：
$ 998.54万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2021-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9261656
关键词：
Academia Adult Area Award Biological Models Biotechnology Cell model Center for Translational Science Activities Chemicals Childhood Clinical Clinical Research Clinical Sciences Clinical and Translational Science Awards Congresses Development Devices Discipline Disease Dose Drug Approval Drug Exposure Drug effect disorder Educational process of instructing Evolution Faculty Fostering Functional disorder Funding Geography Growth Home environment Human Institutes Institution Longevity Marketing Measures Mission Modeling Pediatric Hospitals Pennsylvania Pharmaceutical Preparations Pharmacologic Substance Phenotype Philadelphia Physiological Physiology Population Private Sector Process Research Research Personnel Resources Safety Schools Science Signal Transduction Staging The Wistar Institute Therapeutic Time Transcend Translational Research Translations United States National Institutes of Health Universities Vision abstracting clinical investigation interest medical schools novel novel therapeutics pre-clinical precision medicine programs response translational medicine

项目摘要

Contact PD/PI: FITZGERALD, GARRET A OVERALL ABSTRACT/SUMMARY The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people. The two priorities of our CTSA are to foster the field of translational therapeutics and to bridge the pediatric to adult divide across the entire spectrum of clinical and translational science. This section describes how these priorities have influenced the growth of this CTSA Hub and outlines our plans for the coming funding period. Project Summary/Abstract Page 103 Contact PD/PI: FITZGERALD, GARRET A OVERALL NARRATIVE The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people.

联系人 PD/PI：FITZGERALD、GARRET A 全面的摘要/总结转化医学和治疗研究所是 CTSA 的学术所在地佩恩。在过去十年中，ITMAT 的具体目标始终是 (i) 提高能够在细胞概念验证之间进行研究的研究人员数量和模型系统以及（ii）阐明人类生理学、疾病或通过在少数人群中进行强烈的表型分析来确定药物作用。我们的两个优先事项 CTSA 旨在培育转化治疗领域并架起儿科与成人之间的桥梁整个临床和转化科学领域的划分。本节描述这些优先事项如何影响 CTSA 中心的发展并概述我们的计划即将到来的资助期。项目总结/摘要第 103 页联系人 PD/PI：FITZGERALD、GARRET A 全面的叙述转化医学和治疗研究所是 CTSA 的学术所在地佩恩。在过去十年中，ITMAT 的具体目标始终是 (i) 提高能够在细胞概念验证之间进行研究的研究人员数量和模型系统以及（ii）阐明人类生理学、疾病或通过在少数人群中进行强烈的表型分析来确定药物作用。